Global Autologous CAR-T Cell Therapy Market Growth (Status and Outlook) 2024-2030

Global Autologous CAR-T Cell Therapy Market Growth (Status and Outlook) 2024-2030

CAR-T cell therapy is a novel immunotherapy method, abbreviated as chimeric antigen receptor T cells. Autologous CAR-T cell therapy uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.

The global Autologous CAR-T Cell Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Autologous CAR-T Cell Therapy Industry Forecast” looks at past sales and reviews total world Autologous CAR-T Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Autologous CAR-T Cell Therapy sales for 2023 through 2029. With Autologous CAR-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Autologous CAR-T Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global Autologous CAR-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Autologous CAR-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Autologous CAR-T Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Autologous CAR-T Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Autologous CAR-T Cell Therapy.

United States market for Autologous CAR-T Cell Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Autologous CAR-T Cell Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Autologous CAR-T Cell Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Autologous CAR-T Cell Therapy players cover JW (Cayman) Therapeutics, Gilead (Kite Pharma), Bristol Myers Squibb, Novartis, Legend Biotech Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Autologous CAR-T Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Target: CD19
Target: BCMA
Other

Segmentation by Application:
Hematological Tumors
Solid Tumor

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Target: CD19
Target: BCMA
Other

Segmentation by Application:
Hematological Tumors
Solid Tumor

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
JW (Cayman) Therapeutics
Gilead (Kite Pharma)
Bristol Myers Squibb
Novartis
Legend Biotech Corporation

Please note: The report will take approximately 2 business days to prepare and deliver.